Objective To explore the clinical effect of BTK inhibitor combined with basic chemotherapy on newly diagnosed double-expressing diffuse large B-cell lymphoma(DLBCL).Methods Five cases of newly diagnosed MYC and BCL2 double-expressing DLBCL patients admitted to Nanjing First Hospital from November 2020 to March 2022 were retrospectively collected as research subjects.The patient's medical history is collected,and routine examinations,as well as PET-CT,bone marrow cell morphology,immunophenotyping,chromosomal detection and histological morphology,immunohistochemical examination,FISH and other specialized examinations are carried out.Results Five patients with MYC and BCL2 double-expressing DLBCL were initially diagnosed,of which 2 were high-grade B-cell lymphoma with not otherwise specified(HGBL,NOS),2 were CD5-positive double-expressing DLBCL patients.5 patients were given BTK-based combined chemotherapy,After three course of treatment,4 patients achieved CR,1 patient died after two course of treatment with central relapse,4 patients completed 6 courses of combination therapy and 2 courses of consolidation therapy,1 patient received autologous hematopoietic stem cell transplantation,all patients received intrathecal injection to prevent central invasion during treatment.As of October 2023,the median follow-up time was 31 months,and all 4 patients were in complete remission.Conclusion DLBCL patients with double expression of MYC and BCL2 were treated with BTK inhibitor combined with basic chemotherapy has a good effect and the safety is high,but the sample size needs to be expanded for further exploration in the later stage.
diffuse large B-cell lymphomadouble-expressingBTK inhibitor
国家科技期刊平台
NSTL
万方数据
